- Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
- Agreement to utilize PrecisionLife’s combinatorial analytics platform to identify genetic biomarkers that will optimize patient selection across multiple CNS clinical trials
Oxford, UK, and Alachua, US, 15 June 2023 – Life Science Newswire – PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, announced today a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets.
The collaboration will leverage PrecisionLife’s proprietary combinatorial analytics platform to analyze patient genomic profiles and identify target-specific genetic biomarkers for each of Nanopharmaceutics’ CNS drug development programs. These biomarkers will be based on combinations of single nucleotide polymorphisms (SNPs) specifically associated with Nanopharmaceutics’ drugs’ mechanisms of action and the development indication.
As part of the collaboration, PrecisionLife will support Nanopharmaceutics in the clinical development of their CNS programs by identifying patient stratification biomarkers to link the development compounds’ mechanisms of action to the patient subgroups with the highest likelihood of demonstrating positive outcomes in clinical trials, optimizing patient selection. The terms of the collaboration also include an option for Nanopharmaceutics to negotiate an exclusive right to the patient stratification biomarkers discovered through the PrecisionLife platform.
This precision medicine approach has the potential to significantly increase the probability of clinical trial success rates, even in the most complex chronic diseases. Beyond the applications set out in this collaboration, PrecisionLife biomarkers may also serve as invaluable complementary diagnostic tools, expediting the approval of new therapeutic products and facilitating the swift delivery of the latest medicines to patients with unmet medical needs.
Commenting on the collaboration, James Talton, PhD, President and CEO of Nanopharmaceutics, stated: "We're thrilled to partner with PrecisionLife, a company that shares our commitment to creating targeted therapeutic products for patients. By leveraging PrecisionLife’s innovative approach, Nanopharmaceutics aims to enhance the precision and effectiveness of clinical trials for CNS disorders, which have historically presented numerous challenges due to their complexity.”
Steve Gardner, PhD, CEO and Co-founder of PrecisionLife, added: "PrecisionLife excels in the identification of the combinations of genetic and non-genetic features responsible for an individual’s disease subtypes, enabling the design of smaller, faster-to-readout clinical trials targeted at each drug's mechanism of action. We're delighted to support Nanopharmaceutics in their clinical development with precision biomarkers, accelerating and de-risking the development of targeted therapeutic products for patients who urgently need them."
This collaboration between PrecisionLife and Nanopharmaceutics marks a significant milestone in the pursuit of precision medicine for complex chronic diseases, by using mechanistic patient stratification biomarkers to inform clinical trial design and transform the lives of patients.
About PrecisionLife
PrecisionLife is a pioneering techbio company changing the way the world predicts, prevents, and treats chronic disease.
Our mission is to find better, more personalized treatment options for patients with unmet medical needs - driving precision medicine beyond oncology and rare diseases, into complex common diseases that account for over 80% of healthcare spending.
Our innovative combinatorial approach allows us to uncover the deepest insights into disease biology and achieve mechanistic patient stratification even in the most heterogeneous conditions.
With a vast repository of information and intellectual property spanning over 45 indications, we have developed one of the most extensive pipelines for precision targeted therapies. This wealth of knowledge empowers us to inform and de-risk every stage of biopharma innovation, from initial concept to the clinic.
To learn more about our groundbreaking work, please visit us at precisionlife.com. Connect with us on LinkedIn at @PrecisionLifeAI and follow us on Twitter at @PrecisionLifeAI.
About Nanopharmaceutics, Inc. (OTC: TGRP)
Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability.